The drug is approved as a monotherapy after treatment with oxaliplatin, fluoropyrimidine, and irinotecan-containing chemotherapy, or in combination with FOLFOX.

The FDA granted full approval for panitumumab as treatment for patients with wild-type KRAS mCRC based on evidence from the phase 3 PRIME (ClinicalTrials.gov Identifier: NCT00364013) and ASPECCT (ClinicalTrials.gov Identifier: NCT01001377) trials.

Data from a retrospective analysis of the PRIME study and the prospective, pre-defined analyses from the Phase 3 ‘0007 (ClinicalTrials.gov Identifier: NCT01412957) study led to approval of a refined indication for RAS wild-type mCRC.

The ‘0007 study compared the efficacy of panitumumab with best supportive care (BSC) with BSC alone in patients with chemorefractory, KRAS wild-type mCRC.

1. Hot tea consumption in combination with excessive smoking or alcohol use was associated with a higher risk for esophageal cancer. 2. In the absence of excessive alcohol use and smoking, daily tea drinking was not linked to increased risk for esophageal cancer. Evidence Rating ...

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.